We are Rosuvastatin Calcium CAS:147098-20-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests
Storage conditions: -20°C Freezer
| Items of Analysis | Standard of Analysis | Test Results | ||
| Appearance | Off-white to pale yellow powder | Off-white powder | ||
| Specific rotation（°） | +13.0~+18.0 | +17.9 | ||
| Identification | IR | Consistent with the reference | Consistent with the reference | |
| Calcium salt | Positive response | Positive response | ||
| GC | The main peak retention time consistent with the reference | The main peak retention time consistent with the reference | ||
| Water (%，w/w) |
≤3.0 | 2.5 | ||
| Loss on drying (%，w/w) |
≤3.0 | 1.7 | ||
| Relative Substance (%，area，HPLC) |
Single impurity | ≤0.10 | <0.05 | |
| Total impurity | ≤1.0 | <0.05 | ||
| Diastereomer (EP Imp.B) |
≤0.15 | <0.05 | ||
| EP Imp.A | ≤0.10 | Not detected | ||
| 5-Keto acid (EP Imp.C) |
≤0.10 | <0.05 | ||
| Assay (%, ESTD, HPLC) |
98.0-102.0 | 99.7 | ||
| Conclusion | Conforms to Factory Standard | |||
Related News: Huahai started with the development of characteristic APIs and pharmaceutical intermediates. At the same time, using the international cooperation platform and the opportunity of the expiry of patent protection of major international original research drugs, Huahai has extended the industrial chain to downstream high value-added preparations, and formed intermediates and materials The complete industrial chain of medicine and preparation integration.(2S)-5-methoxy-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine,hydrochloride This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire.(NZ)-N-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]hydroxylamine “Out of an abundance of caution and based on the latest advice from leading health experts, we’re closing all our corporate offices, stores and contact centers in mainland China through February 9.”124655-63-6 The Department of Health and Human Services asked the Defense Department to provide several facilities capable of housing at least 250 people in individual rooms through to February 29, the Pentagon said.As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.
| Product Name | |
|---|---|
| 3-Bromo-4-chlorotoluene | View Details |
| sec-butanol Cas:78-92-2 | View Details |
| O-5,6,7,8-Tetrahydro-2-naphtylthiochloroformate | View Details |